<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease - Wang, Y - 2016 | Cochrane Library</title> <meta content="Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease - Wang, Y - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009631.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease - Wang, Y - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009631.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009631.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease" name="citation_title"/> <meta content="Ying Wang" name="citation_author"/> <meta content="The George Institute for Global Health, The University of Sydney" name="citation_author_institution"/> <meta content="Jessica N Ivany" name="citation_author"/> <meta content="Concord Repatriation General Hospital" name="citation_author_institution"/> <meta content="Vlado Perkovic" name="citation_author"/> <meta content="The George Institute for Global Health, The University of Sydney" name="citation_author_institution"/> <meta content="Martin P Gallagher" name="citation_author"/> <meta content="Mark Woodward" name="citation_author"/> <meta content="The George Institute for Global Health, The University of Sydney" name="citation_author_institution"/> <meta content="Meg J Jardine" name="citation_author"/> <meta content="mjardine@georgeinstitute.org.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD009631.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009631.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009631.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009631.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Catheter Obstruction; *Central Venous Catheters; Anticoagulants [*administration &amp; dosage]; Bacteremia [prevention &amp; control]; Catheter‐Related Infections [prevention &amp; control]; Heparin [administration &amp; dosage]; Kidney Failure, Chronic [*therapy]; Platelet Aggregation Inhibitors [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Renal Dialysis [*instrumentation]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009631.pub2&amp;doi=10.1002/14651858.CD009631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009631\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009631\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009631.pub2",title:"Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end\\u2010stage kidney disease",firstPublishedDate:"Apr 4, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009631.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009631.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009631.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009631.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009631.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009631.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009631.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009631.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2927 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009631.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/appendices#CD009631-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/table_n/CD009631StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/table_n/CD009631StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0002">Ying Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0003">Jessica N Ivany</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0004">Vlado Perkovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0005">Martin P Gallagher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0006">Mark Woodward</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information#CD009631-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Meg J Jardine</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information/en#CD009631-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009631.pub2">https://doi.org/10.1002/14651858.CD009631.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009631-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009631-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009631-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009631-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009631-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009631-abs-0001" lang="en"> <section id="CD009631-sec-0001"> <h3 class="title" id="CD009631-sec-0001">Background</h3> <p>Catheter malfunction, including thrombosis, is associated with reduced dialysis adequacy, as well as an increased risk of catheter‐related bacteraemia and mortality. The role of anticoagulants in the prevention of catheter malfunction remains uncertain. </p> </section> <section id="CD009631-sec-0002"> <h3 class="title" id="CD009631-sec-0002">Objectives</h3> <p>This review aimed to compare the prophylactic effect of different anticoagulant agents, preparations, doses and administration on the incidence of central venous haemodialysis catheter‐related malfunction and sepsis in patients with end‐stage kidney disease (ESKD). </p> </section> <section id="CD009631-sec-0003"> <h3 class="title" id="CD009631-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 7 January 2016 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> </section> <section id="CD009631-sec-0004"> <h3 class="title" id="CD009631-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCT) assessing anticoagulants compared with conventional care for the prevention of catheter malfunction in adult patients receiving haemodialysis for ESKD. </p> </section> <section id="CD009631-sec-0005"> <h3 class="title" id="CD009631-sec-0005">Data collection and analysis</h3> <p>The primary outcome was catheter malfunction defined as a catheter blood flow of 200 mL/min or less, or as defined by study authors. Secondary outcomes were catheter‐related bacteraemia, all‐cause mortality and bleeding events. Relative risks (RR) with 95% confidence intervals (CI) for individual studies were pooled using random effects models within treatment classes. Analyses were conducted by class, with subgroup analyses performed of individual agents within classes. </p> </section> <section id="CD009631-sec-0006"> <h3 class="title" id="CD009631-sec-0006">Main results</h3> <p>We included 27 studies (3003 participants) that were followed up for a median of six months. Study interventions included alternative anticoagulant locking solutions (19 studies, 2216 patients), systemic agents (6 studies, 664 patients) and low or no dose heparin (2 studies, 123 patients). The most common comparison treatment was a locking solution of heparin 5000 IU/mL, used in 17 studies. No significant effect on catheter malfunction was observed for alternative anticoagulant locking solutions (RR 0.96, 95% CI 0.74 to 1.26), systemic agents (RR 0.59, 95% CI 0.28 to 1.23), or low or no dose heparin (RR 0.90, 95% CI 0.10 to 8.31). A significant reduction on incidence of catheter‐related bacteraemia was observed for alternative anticoagulant locking solutions (RR 0.46, 95% CI 0.32 to 0.66) but not systemic agents (RR 2.41, 95% CI 0.89 to 6.55), and could not be assessed in reports of low or no dose heparin studies. No significant effect on all‐cause mortality was observed for alternative anticoagulant locking solutions (RR 0.88, 95% CI 0.54 to 1.43) or systemic agents (RR 0.78, 95% CI 0.37 to 1.65), and was not reported in studies of low or no dose heparin. Bleeding events were only reported in eight studies, including only 2/5 studies of systemic warfarin, with no clear effect demonstrated (RR 1.43, 95% CI 0.86 to 2.39). For individual agents, recombinant tissue plasminogen (rt‐PA) was the only locking solution shown to reduce catheter malfunction (RR 0.58, 95% CI 0.37 to 0.91) based on the results of a single study. No significant on catheter malfunction was observed for other individual classes of alternative anticoagulant locking solutions (citrate: RR 1.14, 95% CI 0.76 to 1.69; antibiotic: RR 1.48, 95% CI 0.79 to 2.77; ethanol: RR 0.88, 95% CI 0.21 to 3.67). On the other hand, all individual classes of alternative anticoagulant locking solutions, except ethanol, reduced catheter‐related bacteraemia (citrate: RR 0.49, 95% CI 0.36 to 0.68; antibiotic: RR 0.27, 95% CI 0.11 to 0.70; rt‐PA: RR 0.35, 95% CI 0.13 to 0.93; ethanol: RR 0.33, 95% CI 0.03 to 4.05). No significant effect on all‐cause mortality was observed for any individual agent within the class of alternative locking solutions. Studies were mainly of low quality and underpowered with an average participant number of 75 and study duration of six months. The interpretation of the study evidence was further limited by the variation in tested interventions and outcome reporting. </p> </section> <section id="CD009631-sec-0007"> <h3 class="title" id="CD009631-sec-0007">Authors' conclusions</h3> <p>The relative net benefit of anticoagulant therapies for prevention of catheter malfunction remains uncertain. Multiple agents appear to reduce catheter‐related bacteraemia although the lack of clear assessment of harms and the limitations of study quality mean these results should be interpreted with caution. Methodological approaches can be used to avoid methods of reporting unduly affecting on the results of meta‐analyses incorporating studies employed mixed reporting methods. Further high quality randomised studies, including safety outcomes, are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009631-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009631-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009631-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009631-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009631-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009631-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009631-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009631-abs-0003" lang="en"> <h3>Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease </h3> <p><b>Background</b> </p> <p>Patients with end‐stage kidney disease require vascular access during haemodialysis. Central venous haemodialysis catheters are frequently used when permanent vascular access is not available. Catheter problems contribute to greater morbidity and mortality. Catheter malfunction leads to requirements for additional interventions, increased risk of catheter‐related infection and hospitalisation. </p> <p>Standard care for the prevention of catheter malfunction is the use of heparin solutions as a post dialysis ‘lock’ in the catheter ports. The potential impact of heparin treatment on bleeding risk is an acknowledged concern. Therefore newer approaches have been proposed to seek improvements in catheter patency or treatment‐associated harm rates. </p> <p><b>Study characteristics</b> </p> <p>This review focused on randomised controlled trials (RCTs) of anticoagulants compared with conventional care for the prevention of catheter malfunction patients receiving haemodialysis. </p> <p><b>Key results</b> </p> <p>We found 27 studies, involving 3003 patients followed for an average six months, which assessed alternative anticoagulant locking solutions, systemic agents and low or no dose heparin. Catheter malfunction were not affected by any of these classes of agents. Subgroup analysis showed that the only agent reducing catheter malfunction was recombinant tissue plasminogen locking solution based on the results of a single study. A significant reduction was observed on the incidence of catheter‐related bacteraemia for alternative anticoagulant locking solutions. There was no evidence to suggest that alternative anticoagulants to heparin locking solutions had an effect on death rates or bleeding events, although only a small proportion of studies reported bleeding events. </p> <p><b>Quality of the evidence</b> </p> <p>Further high quality information is needed on both potential benefits and safety of alternative approaches to maintaining dialysis access catheter function. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009631-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009631-sec-0081"></div> <h3 class="title" id="CD009631-sec-0082">Implications for practice</h3> <section id="CD009631-sec-0082"> <p>The current evidence does not show a clear benefit for alternative anticoagulants compared with conventional practice. Despite the frequency with which this basic aspect of a costly health care service is delivered, we have a limited understanding of its efficacy, safety and cost effectiveness. A net benefit of rt‐PA for prevention of catheter malfunction needs to be confirmed in other settings. Effect of citrate locking solutions on a reduction of catheter‐related bacteraemia is promising, which could potentially replace conventional heparin locking solutions for dialysis patients. However, it warrants further investigation on its benefits and harms before widespread use in clinical practice. </p> </section> <h3 class="title" id="CD009631-sec-0083">Implications for research</h3> <section id="CD009631-sec-0083"> <p>Further high quality blinded RCTs on alternative anticoagulant locking solutions that are adequately powered to report on both potential benefits and harms are needed. Interventions for prevention of catheter malfunction that warrant further investigation include studies of rt‐PA, citrate, and ethanol locking solutions as well as non‐inferiority studies of lower heparin dosing. Given that our review did not show that high citrate concentrations were more efficacious than lower concentrations in preventing catheter malfunction and catheter‐related bacteraemia, it would also appear reasonable that future studies of citrate therapy assess the impact of low concentration citrate locking solutions. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009631-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009631-sec-0022"></div> <p>Central venous haemodialysis catheters are a necessary but problematic component of dialysis practice. Central venous catheters (CVC) are used for approximately 57% of incident dialysis patients in Australia among whom they are associated with significantly increased dialysis‐related mortality (<a href="./references#CD009631-bbs2-0056" title="HariharanS . Recommendations for outpatient monitoring of kidney transplant recipients. American Journal of Kidney Diseases.2006;47(4 Suppl 2):S22‐36. [MEDLINE: 16567238] ">Hariharan 2006</a>; <a href="./references#CD009631-bbs2-0068" title="PolkinghorneKR , ChinGK , MacGinleyRJ , OwenAR , RussellC , TalaulikarGS , et al. KHA‐CARI Guideline: vascular access‐central venous catheters, arteriovenous fistulae and arteriovenous grafts.[Erratum appears in Nephrology (Carlton). 2014 Jan;19(1):64]. Nephrology2013;18(11):701‐5. [MEDLINE: 23855977] ">Polkinghorne 2013</a>; <a href="./references#CD009631-bbs2-0069" title="SchwabSJ , BeathardG . The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney International1999;56(1):1‐17. [MEDLINE: 10411674] ">Schwab 1999</a>; <a href="./references#CD009631-bbs2-0077" title="US Renal DataSystem . USRDS 2009 Annual Data Report: Atlas of chronic kidney disease and end‐stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. www.usrds.org/atlas09.aspx (accessed 6 January 2016). ">USRDS 2009</a>). CVC are associated with the risk of catheter‐related thrombosis which can result in catheter malfunction (<a href="./references#CD009631-bbs2-0072" title="SuhockiPV , ConlonPJJr , KnelsonMH , HarlandR , SchwabSJ . Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. American Journal of Kidney Diseases1996;28(3):379‐86. [MEDLINE: 8804236] ">Suhocki 1996</a>). </p> <section id="CD009631-sec-0023"> <h3 class="title" id="CD009631-sec-0023">Description of the condition</h3> <p>Catheter‐related thrombosis can be classified as either extrinsic or intrinsic (<a href="./references#CD009631-bbs2-0053" title="BeathardGA . Catheter thrombosis. Seminars in Dialysis2001;14(6):441‐5. [MEDLINE: 11851930] ">Beathard 2001</a>) based on the site at which the thrombosis forms. The main consequences from catheter‐related thrombotic events are deep venous thrombosis (<a href="./references#CD009631-bbs2-0078" title="VanherweghemJL . Thrombosis and stenosis of central venous access in hemodialysis [Thromboses et stenoses des acces veineux centraux en hemodialyse]. Nephrologie1994;15(2):117‐21. [MEDLINE: 8047195] ">Vanherweghem 1994</a>), shortened access life and requirement for extra procedures (<a href="./references#CD009631-bbs2-0061" title="LinenbergerML . Catheter‐related thrombosis: risks, diagnosis, and management. Journal of the National Comprehensive Cancer Network2006;4(9):889‐901. [MEDLINE: 17020667] ">Linenberger 2006</a>), inadequate dialysis (<a href="./references#CD009631-bbs2-0062" title="LittleMA , O'RiordanA , LuceyB , FarrellM , LeeM , ConlonPJ , et al. A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrology Dialysis Transplantation2001;16(11):2194‐200. [MEDLINE: 11682667] ">Little 2001</a>) and increased risk of sepsis (<a href="./references#CD009631-bbs2-0074" title="TimsitJF , FarkasJC , BoyerJM , MartinJB , MissetB , RenaudB , et al. Central vein catheter‐related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter‐related sepsis. Chest1998;114(1):207‐13. [MEDLINE: 9674471] ">Timsit 1998</a>). The incidence of catheter‐related thrombosis varies by catheter location (<a href="./references#CD009631-bbs2-0075" title="TrerotolaSO , Kuhn‐FultonJ , JohnsonMS , ShahH , AmbrosiusWT , KneebonePH . Tunneled infusion catheters: Increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology2000;217(1):89‐93. [MEDLINE: 11012428] ">Trerotola 2000</a>), sex, systemic prothrombotic states, site of insertion (subclavian compared with internal jugular) (<a href="./references#CD009631-bbs2-0075" title="TrerotolaSO , Kuhn‐FultonJ , JohnsonMS , ShahH , AmbrosiusWT , KneebonePH . Tunneled infusion catheters: Increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology2000;217(1):89‐93. [MEDLINE: 11012428] ">Trerotola 2000</a>), previous catheter‐related thrombosis and catheter malposition (<a href="./references#CD009631-bbs2-0060" title="LiangosO , GulA , MadiasNE , JaberBL . Long‐term management of the tunneled venous catheter. Seminars in Dialysis2006;19(2):158‐64. [MEDLINE: 16551295] ">Liangos 2006</a>; <a href="./references#CD009631-bbs2-0075" title="TrerotolaSO , Kuhn‐FultonJ , JohnsonMS , ShahH , AmbrosiusWT , KneebonePH . Tunneled infusion catheters: Increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology2000;217(1):89‐93. [MEDLINE: 11012428] ">Trerotola 2000</a>). </p> </section> <section id="CD009631-sec-0024"> <h3 class="title" id="CD009631-sec-0024">Description of the intervention</h3> <p>Current guidelines recommend antithrombotic locking solutions to prevent catheter‐related malfunction in dialysis patients but do not refer to specific agents or concentrations in recognition of the lack of definitive evidence for individual regimens (<a href="./references#CD009631-bbs2-0076" title="UK Renal Association. Vascular access for haemodialysis, 2011. www.renal.org/guidelines/modules/vascular‐access‐for‐haemodialysis#sthash.xgBUlJxx.dpbs (accessed 6 January 2016). ">UK Renal Association 2011</a>; <a href="./references#CD009631-bbs2-0059" title="KDOQI . Clinical practice guidelines and clinical practice recommendations for vascular access 2006. American Journal of Kidney Diseases2006;48(Suppl 1):S176–322. ">KDOQI 2006</a>). Newer approaches including alternative anticoagulant containing locking solutions, antibiotic containing lock solutions, systematic anticoagulants, antiplatelet agents (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>), catheter flushing regimes (<a href="./references#CD009631-bbs2-0066" title="PepperRJ , GaleDP , WajedJ , BommayyaG , AshbyD , McLeanA , et al. Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodialysis International2007;11(4):430‐4. [MEDLINE: 17922740] ">Pepper 2007</a>) and recombinant tissue‐type plasminogen activator (rt‐PA) (<a href="./references#CD009631-bbs2-0041" title="SchenkP , RosenkranzAR , WolflG , HorlWH , TraindlO . Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. American Journal of Kidney Diseases2000;35(1):130‐6. [MEDLINE: 10620554] ">Schenk 2000</a>) have been investigated to seek improvements in catheter patency or treatment‐associated harm rates.  </p> </section> <section id="CD009631-sec-0025"> <h3 class="title" id="CD009631-sec-0025">How the intervention might work</h3> <p>Standard care in the prevention of catheter malfunction is the use of heparin solutions as a post dialysis ‘lock’ in the catheter ports. Heparin is a mucopolysaccharide with in vitro and in vivo anticoagulant properties. It exerts anticoagulant effect by deactivating activated factor X and inhibiting conversion of prothrombin to thrombin. Heparin locking solutions have been recommended for maintaining catheter patency, though the nominated wide concentration range of 1000 to 10,000 U/mL reflects the lack of evidence on optimal dosing (<a href="./references#CD009631-bbs2-0054" title="BesarabA , PandeyR . Catheter management in hemodialysis patients: delivering adequate flow. Clinical Journal of the American Society of Nephrology: CJASN2011;6(1):227‐34. [MEDLINE: 21115628] ">Besarab 2011</a>). The potential impact on bleeding risk is an acknowledged concern (<a href="./references#CD009631-bbs2-0064" title="MoritzML , VatsA , EllisD . Systemic anticoagulation and bleeding in children with hemodialysis catheters. Pediatric Nephrology2003;18(1):68‐70. [MEDLINE: 12488995] ">Moritz 2003</a>; <a href="./references#CD009631-bbs2-0080" title="YevzlinAS , SanchezRJ , HiattJG , WashingtonMH , WakeenM , HofmannRM , et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Seminars in Dialysis2007;20(4):351‐4. [MEDLINE: 17635828] ">Yevzlin 2007</a>). Other adverse events associated with heparin use include major bleeding, heparin‐induced thrombocytopenia and thrombosis, and osteoporosis (<a href="./references#CD009631-bbs2-0073" title="ThomasCM , ZhangJ , LimTH , Scott‐DouglasN , HonsRB , HemmelgarnBR , et al. Concentration of heparin‐locking solution and risk of central venous hemodialysis catheter malfunction. ASAIO Journal2007;53(4):485‐8. [MEDLINE: 17667236] ">Thomas 2007</a>). </p> <p>Alternative approaches, therefore, have been tested to improve catheter function and reduce adverse events. These potentially include alternative anticoagulant based locking solutions (e.g. citrate locking solutions), systemic anticoagulation, and impregnated catheters. These may improve efficacy by their anticoagulant properties. For example, solutions containing 4% to 5% of trisodium citrates express anticoagulant activity (<a href="./references#CD009631-bbs2-0079" title="vonBrechtJH , FlaniganMJ , FreemanRM , LimVS . Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. American Journal of Kidney Diseases1986;8(3):196‐201. [MEDLINE: 3752075] ">von Brecht 1986</a>) by binding Ca²<sup>+</sup> to prevent progression of the coagulation cascade (<a href="./references#CD009631-bbs2-0067" title="PinnickRV , WiegmannTB , DiederichDA . Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. New England Journal of Medicine1983;308(5):258‐61. [MEDLINE: 6848936] ">Pinnick 1983</a>). Alternative approaches to reducing adverse events include reduced heparin or no heparin saline flushes. </p> </section> <section id="CD009631-sec-0026"> <h3 class="title" id="CD009631-sec-0026">Why it is important to do this review</h3> <p>Catheter thrombosis is associated with negative outcomes including reduced dialysis adequacy, requirement for repeated invasive interventions, increased risk of catheter‐related bacteraemia and higher rates of hospitalisation and mortality. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009631-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009631-sec-0027"></div> <p>This review aimed to compare the prophylactic effect of different anticoagulant agents, preparations, doses and administration on the incidence of central venous haemodialysis catheter‐related malfunction and sepsis in patients with ESKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009631-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009631-sec-0028"></div> <section id="CD009631-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009631-sec-0030"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) in which any locking solutions containing anticoagulant, systemic anticoagulants and antiplatelet agents were used for catheter‐related thrombosis prophylaxis. The first phase of randomised cross‐over studies were also included. </p> </section> <section id="CD009631-sec-0031"> <h4 class="title">Types of participants</h4> <section id="CD009631-sec-0032"> <h5 class="title">Inclusion criteria</h5> <p>Studies conducted in people with ESKD who require CVC for initiation or maintenance haemodialysis access were included. Studies enrolling patients who had been treated previously with anticoagulants for thrombotic events were included in the review. </p> </section> <section id="CD009631-sec-0033"> <h5 class="title">Exclusion criteria</h5> <p>Studies that included patients who were receiving systemic therapeutic anticoagulation for non catheter‐related thromboembolic events were excluded. Patients with acute kidney injury were also excluded. </p> </section> </section> <section id="CD009631-sec-0034"> <h4 class="title">Types of interventions</h4> <p>The review compared the prophylactic effect of different anticoagulant or antiplatelet agents, preparations, doses and administration on the incidence of central venous haemodialysis catheter‐related malfunction and sepsis in patients with ESKD. We conducted comparisons of placebos or comparators versus: </p> <p> <ul id="CD009631-list-0001"> <li> <p>anticoagulant catheter locking solutions;</p> </li> <li> <p>systemic anticoagulants;</p> </li> <li> <p>antiplatelet agents.</p> </li> </ul> </p> </section> <section id="CD009631-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD009631-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009631-list-0002"> <li> <p>Reported thrombotic outcomes: Incidence of catheter malfunction presumed due to thrombosis defined as a persistent inability to achieve a blood flow of greater than 200 mL/min despite positional changes of the patient and additional flushing or both, or as defined by the study authors. </p> </li> </ul> </p> </section> <section id="CD009631-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009631-list-0003"> <li> <p>Incidence of major bleeding, defined as a reduction in haemoglobin of 20 g/L; bleeding requiring blood transfusion, bleeding requiring hospital admission, or as defined by the authors </p> </li> <li> <p>Incidence of minor bleeding, defined as a reduction in haemoglobin of less than 20 g/L, change from baseline less than 19.9 g/L; bleeding not requiring hospital admission, bleeding not requiring blood transfusion, or as defined by the authors </p> </li> <li> <p>Other thrombotic events, defined as thromboses in vessels in the region of the vascular catheter, or as defined by the study authors </p> </li> <li> <p>Requirement for replacement of CVC</p> </li> <li> <p>Requirement for thrombolytic agents</p> </li> <li> <p>Infection related to vascular access, defined as catheter‐related exit site infection, bacteraemia in the absence of another clear source of infection, or as defined by the study authors </p> </li> <li> <p>Thrombocytopenia, defined as a new platelet count less than 150,000/μL (150 x 10⁹/L), or as defined by the study authors </p> </li> <li> <p>Hypocalcaemia, defined as a serum corrected calcium level less than 2.20 mmol/L, or as defined by the study authors </p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Other adverse events including allergic reactions, urticaria, and anaphylaxis</p> </li> <li> <p>Other adverse events, as defined by the study authors</p> </li> <li> <p>Economic costs to health services funders.</p> </li> </ul> </p> </section> </section> </section> <section id="CD009631-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009631-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched Cochrane Kidney and Transplant's Specialised Register to 7 January 2016 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD009631-list-0004"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD009631-sec-0087">Appendix 1</a> for search terms. </p> </section> <section id="CD009631-sec-0040"> <h4 class="title">Searching other resources</h4> <p>Relevant studies were also obtained from the following sources.</p> <p> <ol id="CD009631-list-0005"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD009631-sec-0041"> <h3 class="title" id="CD009631-sec-0041">Data collection and analysis</h3> <section id="CD009631-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two authors independently reviewed the abstracts of all studies from the initial search. Those that meet the inclusion criteria were collated. Two authors independently applied the inclusion criteria to each full text article. A third author resolved any conflicts by acting as arbitrator. There were three ways we dealt with duplicate publications. Firstly, we used Endnote’s ‘find duplicate’ function to automatically remove duplicates. Secondly, we manually screened the duplications when we went through abstracts review. Thirdly, when one study produced more than one publication, we combined reports together and used the publication with the most complete data in the analyses. The number of duplicates is reported in the study flow chart. </p> </section> <section id="CD009631-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>Two authors independently extracted information using a standardised data collection form. These data were extrapolated from tables and graphs in published papers. If this is not possible, the study authors were contacted for further information. Extracted data included clinical measures such as participants' comorbidities, and length and frequency of dialysis. We also scrutinised information regarding interventions, different anticoagulants, and assess data related to our primary and secondary outcomes measures. </p> </section> <section id="CD009631-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD009631-bbs2-0058" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD009631-sec-0088">Appendix 2</a>). </p> <p> <ul id="CD009631-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD009631-list-0007"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Were reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD009631-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>For the primary outcome, incidence of thromboembolic events, and secondary outcomes with continuous variables (such as rates of bleeding and rates of other adverse effects), we treated data as continuous and use mean differences to estimate the difference that one treatment has on the average outcome to another. However, if results were reported as time to a first event, we used time‐to‐event data to measure treatment effect. </p> <p>For binary outcomes, such as all‐cause mortality, we compared proportions and 95% confidence intervals, and calculate numbers‐needed‐to‐treat and numbers‐needed‐to‐harm to establish a standardised, clinically relevant measure of data. </p> <p>An a priori decision was made to calculate summary estimates within three therapeutic classes (i.e. alternative anticoagulant locking solutions, systemic agents, and low or no dose heparin locking solutions) given the different mechanisms of action between classes and the plausible true heterogeneity of effect. Studies varied in the method of outcome reporting. We nominated heparin 5000 IU/ml as the comparison arm where possible, based on clinical practice despite the lack of evidence‐based recommendations from current guidelines on optimal heparin lock concentration (<a href="./references#CD009631-bbs2-0054" title="BesarabA , PandeyR . Catheter management in hemodialysis patients: delivering adequate flow. Clinical Journal of the American Society of Nephrology: CJASN2011;6(1):227‐34. [MEDLINE: 21115628] ">Besarab 2011</a>). </p> </section> <section id="CD009631-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed outcomes at the individual patient level. If the unit of randomisation was not the same as the level of analysis, i.e. the patient, adjustments were made to address the potential impact of clustering on the outcome. </p> </section> <section id="CD009631-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Missing data were requested by written correspondence (e.g. emailing corresponding author) from the authors. </p> </section> <section id="CD009631-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD009631-bbs2-0057" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> <p>An a priori decision was made to calculate summary estimates within three therapeutic classes (i.e. alternative anticoagulant locking solutions, low or no dose heparin locking solutions and systemic agents) given the different mechanisms of action between classes and the plausible true heterogeneity of effect. </p> </section> <section id="CD009631-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were to be used to assess for the potential existence of small study bias (<a href="./references#CD009631-bbs2-0058" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If there was funnel plot asymmetry we planned to use the trim‐and‐fill method to estimate the volume of unpublished studies on this concept. </p> </section> <section id="CD009631-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Relative risks (RR) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. By preference we selected data reported as the number of patients with an event. However, where data was not available for the number of patients with an event, we included data reported as events per study and then as events per catheter day, by deriving a RR for each study and pooling the RRs as below. </p> <p>Given the heterogeneity of the interventions involved, our pre‐specified preference was to use random effects models to derive the summary estimates. However, we observed a variety of methods of outcome reporting including reporting by patients and reporting of repeated events. The random effects model weights individual studies by confidence interval with the consequence that any given study will have greater influence on the overall result if repeated events measures are used compared with if patient counts are used. Having the results influenced by decisions on reporting method appears arbitrary and could have the overall effect of favouring smaller studies as these may be more likely to report event rates rather than counts, and so does not seem consistent with the conservative approach underlying our initial decision to use random effects models. We therefore modified our analysis methods as follows. Summary estimates of relative risks were derived from individual study risks in a two‐step process. Firstly random effects models were constructed pooling individual studies that reported by each method. Secondly the results of these models were weighted by average study sample size. </p> <p>Analyses were performed using RevMan 5.3 if possible, i.e. where all studies reported the raw counts of participants experiencing an event. When this was not possible, analyses were performed using <a href="./references#CD009631-bbs2-0071" title="StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. ">STATA 11.0</a>. </p> </section> <section id="CD009631-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Planned a priori subgroup analyses were used to explore possible sources of heterogeneity. Heterogeneity in prevention of catheter malfunction in alternative anticoagulant locking solutions could be related to different class of interventions, i.e. citrate, rt‐PA, LMWH and antibiotic locking solutions. Whether the use of a co‐intervention or not can also cause heterogeneity of the results, which was also analysed. </p> </section> <section id="CD009631-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity study was performed according to Cochrane methodology, i.e. by substituting alternative decisions or ranges of values for decisions that were arbitrary or unclear, including the omission of single studies whose inclusion alters the analysis outcome. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009631-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009631-sec-0053"></div> <section id="CD009631-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD009631-sec-0055"> <h4 class="title">Results of the search</h4> <p>The search identified 448 potentially relevant studies, of which 52 studies with 71 reports were reviewed in full text (<a href="./references#CD009631-sec-0093" title="">Characteristics of included studies</a>). Twenty seven studies were included, 16 studies excluded and there are nine studies awaiting assessment: seven were abstract‐only publications (<a href="./references#CD009631-bbs2-0044" title="BonkainF , RacapeJ , GoncalvezI , MoermanM , DenisO , GammarN , et al. Prevention of tunneled cuffed hemodialysis catheter‐related dysfunction and bacteremia by a neutral‐valve closed‐system connector: a single‐center randomized controlled trial. American Journal of Kidney Diseases2013;61(3):459‐65. [MEDLINE: 23228946] ">Bonkain 2013</a>; <a href="./references#CD009631-bbs2-0045" title="ClementJD , HasbargenJA . Low dose warfarin fails to improve survival of tunneled dialysis catheters [abstract no: M300]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):169A. [CENTRAL: CN‐00444852] ">Clement 1998</a>; <a href="./references#CD009631-bbs2-0046" title="FreudigerH , GluckZ , MeyerK . Comparison of prophylactic filling in central venous hemodialysis catheters with heparin or urokinase: preliminary results in 21 patients [abstract]. Kidney International1990;37(4):1181. FreudigerH , GluckZ , MeyerK . Comparison of prophylactic filling of central venous hemodialysis catheters with heparin or urokinase [abstract]. Kidney International1990;38(2):370. ">Freudiger 1990</a>; <a href="./references#CD009631-bbs2-0047" title="GeronR , TanhilevskyO , TanasijitchoukT , RubinchikI , KristalB . Addition of heparin to Taurolock™ catheter lock solution (CLS) ‐ does it improve tunnel cuffed catheter (TCC) patency dysfunction? [abstract no: F‐PO1597]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):466A. ">Geron 2008</a>; <a href="./references#CD009631-bbs2-0048" title="HemmelderMH , Knot‐VeldhuisIJ , EngelageG , FranssenCF . Heparin lock in hemodialysis catheters adversely affects clotting times: a comparison of three catheter sampling methods [abstract no: SU‐PO883]. Journal of the American Society of Nephrology2003;14(Nov):729A. [CENTRAL: CN‐00583316] ">Hemmelder 2003</a>; <a href="./references#CD009631-bbs2-0051" title="ShiM , ChenH , LiuH , QiuC , JiaR , DingG . Anticoagulant effect of argatroban in ESRD patients during induction period of hemodialysis with central venous catheter access [abstract no: F‐PO1582]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):462A. ">Shi 2008</a>; <a href="./references#CD009631-bbs2-0052" title="SishirG , BhupeshkumarK , UmapatiH , KalpeshG , MohanR . To study the efficacy of intraluminal 70% ethanol vs heparin lock prior to hemodialysis in prevention of infections in non‐tunneled hemodialysis catheters: A randomised study [abstract]. Nephrology2014;19(Suppl 2):181‐2. [EMBASE: 71617247] ">Sishir 2014</a>); one study was recently completed and no data are available (<a href="./references#CD009631-bbs2-0049" title="ISRCTN27307877 . Trisodium citrate versus heparin for locking tunnelled haemodialysis catheters: a randomised controlled trial. www.controlled‐trials.com/ISRCTN27307877 (accessed 6 January 2016). ">ISRCTN27307877</a>); and one study was identified just prior to publication and will be assessed in a future update of this review (<a href="./references#CD009631-bbs2-0050" title="RayCE , ShenoySS , McCarthyPL , BroderickKA , KaufmanJA . Weekly prophylactic urokinase instillation in tunneled central venous access devices. Journal of Vascular &amp; Interventional Radiology1999 Nov;10(10):1330‐4. [MEDLINE: 10584647] ">Ray 1999</a>) (<a href="#CD009631-fig-0001">Figure 1</a>). There were no citations in languages other than English were identified. </p> <div class="figure" id="CD009631-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009631-sec-0056"> <h4 class="title">Included studies</h4> <p>Interventions included alternative anticoagulant locking solutions (19 studies, 2216 patients) (<a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>), systemic agents (aspirin (1 study, 180 patients) (<a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>); warfarin (5 studies, 479 patients) (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>), and low or no dose heparin (2 studies, 123 patients (<a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>). </p> <p>Within the class of alternative anticoagulant locking solutions, agents tested included citrate locking solutions (14 studies, 1656 patients) (<a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>); recombinant tissue plasminogen activator locking solutions (1 study, 225 patients) (<a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>), antibiotic locking solutions (2 studies, 244 patients) (<a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>), low molecular weight heparin (LMWH) locking solutions (1 study, 42 patients) (<a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>), and ethanol locking solution (1 study, 49 patients) (<a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>). </p> </section> <section id="CD009631-sec-0057"> <h4 class="title">Excluded studies</h4> <p>Sixteen studies (22 reports) were excluded after review of the full article (<a href="./references#CD009631-sec-0094" title="">Characteristics of excluded studies</a>). Two studies were not randomised (<a href="./references#CD009631-bbs2-0028" title="AslamS , TrautnerBW , RamanathanV , DarouicheRO . Pilot trial of N‐acetylcysteine and tigecycline as a catheter‐lock solution for treatment of hemodialysis catheter‐associated bacteremia. Infection Control &amp; Hospital Epidemiology2008;29(9):894‐7. [MEDLINE: 18643743] ">Aslam 2008</a>; <a href="./references#CD009631-bbs2-0038" title="OtaK , TeraokaS , AkiwasaT , MimuraN , HirasawaY , SakaiT , et al. Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) ‐A double‐blind comparison with ticlopidine hydrochloride. Rinsho Hyoka1996;24(1):9‐38. [CENTRAL: CN‐00320772] ">Ota 1996</a>); two studies were cross‐over studies with no extractable data (<a href="./references#CD009631-bbs2-0035" title="MeeusG , KuypersDR , ClaesK , EvenepoelP , MaesB , VanrenterghemY . A prospective, randomized, double‐blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters. Blood Purification2005;23(2):101‐5. [MEDLINE: 15640601] ">Meeus 2005</a>; <a href="./references#CD009631-bbs2-0041" title="SchenkP , RosenkranzAR , WolflG , HorlWH , TraindlO . Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. American Journal of Kidney Diseases2000;35(1):130‐6. [MEDLINE: 10620554] ">Schenk 2000</a>);10 studies enrolled the wrong population (<a href="./references#CD009631-bbs2-0029" title="BetjesMG , OosteromD , vanAgterenM , van deWeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH‐FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN‐00671866] ">Betjes 2006</a>; <a href="./references#CD009631-bbs2-0030" title="CaruanaRJ , HallJC , CrowJW , CatoA , SmithMC , ClyneD . Epoprostenol (E) versus heparin (H) for anticoagulation in chronic hemodialysis (HD) [abstract]. Kidney International1989;35(1):242. [CENTRAL: CN‐00644128] CaruanaRJ , SmithMC , ClyneD , CrowJW , ZinnJM , DiehlJH . Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purification1991;9(5‐6):296‐304. [MEDLINE: 1819317] ">Caruana 1991</a>; <a href="./references#CD009631-bbs2-0031" title="GittinsNS , Hunter‐BlairYL , MatthewsJN , CoulthardMG . Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. Archives of Disease in Childhood2007;92(6):499‐501. [MEDLINE: 17068072] ">Gittins 2007</a>; <a href="./references#CD009631-bbs2-0032" title="HuHH , HsuCY , FangHC , LeePT , ChenCL , ChangTY , et al. Low‐dose heparin retention in temporary hemodialysis double‐lumen catheter does not increase catheter occlusion and might reduce risk of bleeding. Blood Purification2011;32(3):232‐7. [MEDLINE: 21829015] ">Hu 2011</a>; <a href="./references#CD009631-bbs2-0033" title="HuraibS , AskarA , Abu‐AishaH , al‐WakeelJ . Prevalence of infection from subclavian dialysis catheters with two different postinsertion catheter cares: a randomized comparative study. Angiology1994;45(12):1047‐51. [MEDLINE: 7985832] ">Huraib 1994</a>; <a href="./references#CD009631-bbs2-0034" title="LangeC , LohofenerC , HallebachG , GenselA , BergmannK , JanuschkewitzK , et al. Low‐dose citrate versus standard heparin for dialysis catheter locking ‐ a randomised, controlled, double‐blind clinical trial interim analysis [abstract no: FP414]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi158. ">Lange 2007</a>; <a href="./references#CD009631-bbs2-0036" title="OguzhanN , PalaC , SipahiogluMH , CilanH , DurmazS , PercinD , et al. Locking tunneled hemodialysis catheters with hypertonic saline (26% NaCl) and heparin to prevent catheter‐related bloodstream infections and thrombosis: a randomized, prospective trial. Renal Failure2012;34(2):181‐8. [MEDLINE: 22260745] ">Oguzhan 2012</a>; <a href="./references#CD009631-bbs2-0039" title="PlamondonI , AgharaziiM , AudyE , LangloisS , DesmeulesS . Randomized cross‐over comparison of 4% citrate and heparin for catheter lock of double‐lumen hemodialysis catheters [abstract no: TH‐FC054]. Journal of the American Society of Nephrology2005;16:12A. ">Plamondon 2005</a>; <a href="./references#CD009631-bbs2-0042" title="ThomsonPC , MorrisST , MactierRA . The effect of heparinized catheter lock solutions on systemic anticoagulation in hemodialysis patients. Clinical Nephrology2011;75(3):212‐7. [MEDLINE: 21329631] ">Thomson 2011</a>; <a href="./references#CD009631-bbs2-0043" title="WeijmerM , van denDorpelR , vanGeelenJ , GroeneveldH , vanJaarsveldB , KoopmansM , et al. Reduction of bleeding complications in hemodialysis patients with high concentration trisodium citrate for hemodialysis catheter locking: a prospective multicenter double‐blind randomised controlled trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):737. WeijmerM , van denDorpelR , vanGeelenJ , GroeneveldH , vanJaarsveldB , KoopmansM , et al. Substantial reduction of infectious complications in hemodialysis patients with trisodium citrate 30% as catheter locking solution: a prospective multicenter double‐blind randomised controlled trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):740. [CENTRAL: CN‐00448318] WeijmerMC , Van denDorpelMA , VanGeelenJA , GroeneveldHO , VanJaarsveldBC , KoopmansMG , et al. Substantial reduction of infectious complications in hemodialysis patients with trisodium citrate 30% as catheter locking solution; a prospective multicenter double‐blind randomised controlled trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):54A. [CENTRAL: CN‐00550712] WeijmerMC , Van denDorpelMA , VanGeelenJACA , GroeneveldHO , VanJaarsveldVC , KoopmansMG , et al. Reduction of bleeding complications in hemodialysis patients with high concentration trisodium citrate for hemodialysis catheter locking; a prospective multicenter double‐blind randomised controlled trial [abstract no: F‐PO825]. Journal of the American Society of Nephrology2003;14(Nov):242A. [CENTRAL: CN‐00448317] WeijmerMC , van denDorpelMA , Van deVenPJ , ter WeePM , vanGeelenJA , GroeneveldJO , et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter‐locking solution in hemodialysis patients. Journal of the American Society of Nephrology2005;16(9):2769‐77. [MEDLINE: 16033861] ">Weijmer 2005</a>); and two studies did not use anticoagulant or antiplatelet agents (<a href="./references#CD009631-bbs2-0037" title="OranNT , EserI . Impact of heparin locking frequency on preventing temporary dialysis catheter dysfunction in haemodialysis patients. Journal of Renal Care2008;34(4):199‐202. [MEDLINE: 19090898] ">Oran 2008</a>; <a href="./references#CD009631-bbs2-0040" title="SaxenaAK , PanhotraB , Al‐AzizA , MorseyMN , VenkateshappaCK , Abu‐OyunB . Optimizing outcomes of tunneled hemodialysis catheters with intraluminal cefotaxime ‐ heparin locks among staphylococcus aureus nasal carriers [abstract no: SA780]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. SaxenaAK , PanhotraBR , Al hafizAA , SundaramDS , Abu‐OyunB , Al MulhimK . Cefotaxime‐heparin lock prophylaxis against hemodialysis catheter‐related sepsis among Staphylococcus aureus nasal carriers. Saudi Journal of Kidney Diseases &amp; Transplantation2012;23(4):743‐54. [MEDLINE: 22805387] ">Saxena 2012</a>). </p> </section> </section> <section id="CD009631-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was variable as illustrated in overall <a href="#CD009631-fig-0002">Figure 2</a> and by individual study in <a href="#CD009631-fig-0003">Figure 3</a>. In the majority of studies as reported, the risk of bias was unclear for random sequence generation and allocation concealment, unclear or high for blinding of participants or personnel, and for outcome assessment. Most studies as reported were low risk for incomplete outcome data reporting and high risk for selective reporting. </p> <div class="figure" id="CD009631-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009631-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009631-sec-0059"> <h4 class="title">Allocation</h4> <section id="CD009631-sec-0060"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was judged to be at low risk of bias in 12/27 (45%) studies (<a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>); unclear in 13/27 (48%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>) and at high risk of bias in 2/27 (7%) studies (<a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>). </p> </section> <section id="CD009631-sec-0061"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was judged to be of low risk in 5/27 (19%) studies (<a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>;<a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>); unclear in 20/27 (74%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>); and at high risk of bias in 2/27 (7%) studies (<a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>). </p> </section> </section> <section id="CD009631-sec-0062"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel (performance bias) was judged to be at low risk of bias in 8/27 (30%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>); unclear in 9/27 (33%) studies (<a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>) and at high risk of bias in 10/27 (37%) studies (<a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>). </p> <p>Blinding of outcome assessors (detection bias) was judged to be of low risk in 3/27 (11%) studies (<a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>), unclear in 15/27 (56%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>); and of high risk in 9/27 (33%) studies (<a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>). </p> </section> <section id="CD009631-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete data was judged to be of low risk in 18/27 (67%) studies (<a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>;<a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>); and unclear in 3/27 (11%) studies (<a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>); and of high risk in 6/27 (22%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>;<a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>). </p> </section> <section id="CD009631-sec-0064"> <h4 class="title">Selective reporting</h4> <p>Low risk for selective reporting was defined as report with at least one catheter malfunction type outcome and safety outcome (bleeding), which was judged in 7/27 (26%) studies (<a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>;<a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>); unclear risk in 2/27 (7%) studies (<a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>); and of high risk in 18/27 (67%) studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>). </p> </section> <section id="CD009631-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <section id="CD009631-sec-0066"> <h5 class="title">Intention‐to‐treat analysis</h5> <p>Intention‐to‐treat analysis was used in 8/27 (30%) studies (<a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>), and was not reported in 19/27 (70%). </p> </section> <section id="CD009631-sec-0067"> <h5 class="title">Funding</h5> <p>Four studies were assessed as being at high risk of bias (<a href="./references#CD009631-bbs2-0002" title="MakiDG , AshSR , WingerRK , LavinP , AZEPTIC Trial Investigators. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi‐center, controlled, randomized trial. Critical Care Medicine2011;39(4):613‐20. [MEDLINE: 21200319] ">AZEPTIC Study 2011</a>; <a href="./references#CD009631-bbs2-0004" title="BleyerAJ , MasonL , RussellG , RaadII , SherertzRJ . A randomized, controlled trial of a new vascular catheter flush solution (minocycline‐EDTA) in temporary hemodialysis access. Infection Control &amp; Hospital Epidemiology2005;26(6):520‐4. [MEDLINE: 16018426] ">Bleyer 2005</a>; <a href="./references#CD009631-bbs2-0017" title="MaloJ , JolicoeurC , TheriaultF , LachaineJ , SenecalL . Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO Journal2010;56(1):42‐7. [MEDLINE: 20051836] MaloJ , JolicoeurC , TheriaultF , SavoieM , ChouinardP , LachaineJ , et al. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock [abstract no: SP592]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv214. [CENTRAL: CN‐00740610] ">Malo 2010</a>; <a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a>); 10 studies were judged to be at low risk of bias (<a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a>; <a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a>; <a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a>; <a href="./references#CD009631-bbs2-0019" title="MoranJ , SunS , KhababaI , PedanA , DossS , SchillerB . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. American Journal of Kidney Diseases2012;59(1):102‐7. [MEDLINE: 22088576] MoranJE , SunSJ , KhababaI , PedanA , DossS , SchillerB . A randomized controlled trial of gentamicin/citrate versus heparin locks for central venous catheters in maintenance hemodialysis [abstract no: LB‐PO3143]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">Moran 2012</a>; <a href="./references#CD009631-bbs2-0021" title="NoriUS , FisherKA , OsmanY , ManoharanA , BesarabA . Efficacy of antibiotic lock solutions in preventing hemodialysis catheter related bacteremia. [abstract no: SU‐FC076]. Journal of the American Society of Nephrology2004;15(Oct):60A. [CENTRAL: CN‐00583540] NoriUS , ManoharanA , YeeJ , BesarabA . Comparison of low‐dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter‐related bacteremia. American Journal of Kidney Diseases2006;48(4):596‐605. [MEDLINE: 16997056] ">Nori 2006</a>; <a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a>; <a href="./references#CD009631-bbs2-0023" title="DuncanN , SinghS , AmaoM , BrownW , DalbyE , EdwardsC , et al. A single centre randomised control trial of sodium citrate versus heparin line locks for cuffed central venous catheters [abstract no: F‐PO539]. Journal of the American Society of Nephrology2005;16:451A. [CENTRAL: CN‐00676330] PowerA , DuncanN , SinghSK , BrownW , DalbyE , EdwardsC , et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single‐center randomized controlled trial. American Journal of Kidney Diseases2009;53(6):1034‐41. [MEDLINE: 19394731] ">Power 2009</a>; <a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>; <a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>; <a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a>), and bias was unclear in 13 studies (<a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a>; <a href="./references#CD009631-bbs2-0003" title="BetjesMG , vanAgterenM . Prevention of dialysis catheter‐related sepsis with a citrate‐taurolidine‐containing lock solution. Nephrology Dialysis Transplantation2004;19(6):1546‐51. [MEDLINE: 14993498] ">Betjes 2004</a>; <a href="./references#CD009631-bbs2-0005" title="ButurovicJ , PonikvarR , KandusA , BohM , KlinkmannJ , IvanovichP . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs1998;22(11):945‐7. [MEDLINE: 9821527] ">Buturovic 1998</a>; <a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a>; <a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a>; <a href="./references#CD009631-bbs2-0009" title="CorbettR , AshbyD , EdwardsD , EdwardsC , ProutV , SinghS , et al. A randomised control trial of taurolidine‐heparin‐citrate line locks in prevention of recurrence of catheter related bacteraemia in haemodialysis patients [abstract no: SO063]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i19. ">Corbett 2013</a>; <a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a>; <a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a>; <a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a>; <a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a>; <a href="./references#CD009631-bbs2-0016" title="LustigA , AflaluS . Novel catheter lock solution in prevention of hemodialysis catheter complications [abstract no: 1121942]. Journal of Clinical Pharmacology2011;51(9):1341. [EMBASE: 70645124] ">Lustig 2011</a>; <a href="./references#CD009631-bbs2-0020" title="MozafarM , SamsamiM , SobhiyehMR , JabbehdariS , Fallah ZavarehM . Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly2013;5(2):762‐5. [MEDLINE: 23841041] ">Mozafar 2013</a>; <a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a>). </p> </section> </section> </section> <section id="CD009631-sec-0068"> <h3 class="title" id="CD009631-sec-0068">Effects of interventions</h3> <section id="CD009631-sec-0069"> <h4 class="title">Prevention of catheter malfunction</h4> <p>We were able to assess the incidence of catheter malfunction in 16/27 studies (1490 patients) with a median follow‐up of six months. There were 159 catheter malfunction events in 753 participants in the intervention group, and 199 events in 737 participants in the control group. In addition, catheter malfunction events were reported in different ways. Four studies assessed catheter loss, five studies assessed thrombosis, and one study assessed requirement for intervention to maintain catheter function (<a href="#CD009631-tbl-0001">Table 1</a>). There was no effect for alternative anticoagulant locking solutions (<a href="#CD009631-fig-0004">Figure 4</a> (9 studies, 908 patients): RR 0.96, 95% CI 0.74 to 1.26), systemic warfarin (<a href="#CD009631-fig-0004">Figure 4</a> (6 studies, 460 patients): RR 0.59, 95% CI 0.28 to 1.23), and low or no dose heparin (<a href="#CD009631-fig-0004">Figure 4</a> (2 studies, 123 patients): RR 0.90, 95% CI 0.10 to 8.31). </p> <div class="figure" id="CD009631-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Catheter malfunction" data-id="CD009631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Catheter malfunction</p> </div> </div> </div> <div class="table" id="CD009631-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Catheter malfunction events reported by study authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> <p><b>Definition of<br/> malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Overall malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Sub‐classification of catheter malfunction events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss due to<br/> malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Catheter duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions<br/> to maintain<br/> catheter function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Venous occlusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Alternative anticoagulant locking solutions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a> </p> <p>BFR &lt; 200 mL/min for non‐tunnelled and 250 mL/min for tunnelled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 20/92</p> <p>Cont: 14/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 20/92</p> <p>Cont: 14/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 13/32</p> <p>Cont: 12/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 25%</p> <p>Cont: 17.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 55 days</p> <p>Cont: 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 13/42</p> <p>Cont: 16/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 9/59</p> <p>Cont: 11/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a> </p> <p>Catheter removal due to flow difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 5/10</p> <p>Cont: 5/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 105 non‐occlusive clots</p> <p>Cont: 44 non‐occlusive clots</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/14</p> <p>Cont: 6/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 18/110</p> <p>Cont: 36/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/110</p> <p>Cont: 1/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a> </p> <p>Catheter loss due to occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Systematic anticoagulants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a> </p> <p>Catheter thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/20</p> <p>Cont: 9/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 75% survival at 12 months</p> <p>Cont: 36.8% survival at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/20</p> <p>Cont: 9/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a> </p> <p>BFR &lt; 300 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 10/81</p> <p>Cont: 33/63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a> </p> <p>BFR &lt; 300 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nor reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/10</p> <p>Cont: 1/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 188 days</p> <p>Cont: 356 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a> </p> <p>BFR &lt; 150 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> No or low dose heparin locking solution</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a> </p> <p>Catheter thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/37</p> <p>Cont: 0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/37</p> <p>Cont: 0/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a> </p> <p>Catheter thrombosis or BFR &lt; 140 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/26</p> <p>Cont: 1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/26</p> <p>Cont: 1/22</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BFR ‐ blood flow rate; Cont ‐ control; Int ‐ intervention</p> </div> </div> <p>Subgroup analysis of the impact of individual locking solution agents demonstrated that only rt‐PA was associated with a reduction of catheter malfunction (<a href="#CD009631-fig-0005">Figure 5</a> (1 study, 225 patients): RR 0.58, 95% CI 0.37 to 0.91). Citrate locking solutions of concentrations ranging from 4% to 46.7% did not significantly reduce catheter malfunction (<a href="#CD009631-fig-0005">Figure 5</a> (6 studies, 447 patients): RR 1.14, 95% CI 0.76 to 1.69), regardless of use in isolation or in conjunction with anti‐microbial solutions including gentamicin, taurolidine or methylene blue (regression coefficient for adjuvant antibiotics compared with none: 0.455, P = 0.167). High citrate concentration was not superior to low concentration (regression coefficient for citrate concentration 0.143, P = 0.605). </p> <div class="figure" id="CD009631-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Catheter malfunction (subgroup analysis)" data-id="CD009631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Catheter malfunction (subgroup analysis)</p> </div> </div> </div> <p>Among the studies of systemic anticoagulation, there was no suggestion of a dose related effect of warfarin on prevention of catheter malfunction although only five eligible studies were identified (regression coefficient for warfarin dose ‐0.992, P = 0.108). The dosage of warfarin and the target INRs in systemic anticoagulants studies was summarised in <a href="#CD009631-tbl-0002">Table 2</a>. </p> <div class="table" id="CD009631-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Warfarin dosage and target INR in systemic anticoagulant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Background care</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.5 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinzaparin 40 to 50 IU/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.8 to 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin after catheter malfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ticlopidine 250 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose warfarin 1 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin 5000 U/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose warfarin 1 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.5 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin 1000 to 10,000 U/mL</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>INR ‐ international normalised ratio</p> </div> </div> <p>Sensitivity analysis demonstrated the impact of citrate solutions remained non‐significant when a single study of citrate and taurolidine (<a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a>) was excluded (RR 0.85, 95% CI 0.61 to 1.18). Use of warfarin demonstrated a 42% reduction in the incidence of catheter malfunction, however, high heterogeneity among the five warfarin studies exist (I² = 77.6%, P = 0.001). </p> </section> <section id="CD009631-sec-0070"> <h4 class="title">Prevention of catheter‐related bacteraemia</h4> <p>Catheter‐related bacteraemia was assessed in 16 studies (2214 patients, median follow‐up 4 months). The incidence of catheter‐related bacteraemia was reported as the rate per 1000 catheter days in 10 studies, the rate per patient in 14 studies and both in 8 studies. A significant reduction on the rate of catheter‐related bacteraemia was found from alternative anticoagulant locking solutions (<a href="#CD009631-fig-0006">Figure 6</a>: RR 0.46, 95% CI 0.32 to 0.66), but not from systemic warfarin (<a href="#CD009631-fig-0007">Figure 7</a>: RR 2.41, 95% CI 0.89 to 6.55). </p> <div class="figure" id="CD009631-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Catheter‐related bacteraemia" data-id="CD009631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Catheter‐related bacteraemia</p> </div> </div> </div> <div class="figure" id="CD009631-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Catheter‐related bacteraemia (subgroup analysis)" data-id="CD009631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Catheter‐related bacteraemia (subgroup analysis)</p> </div> </div> </div> <p>Subgroup analysis showed a reduction in the rate of catheter‐related bacteraemia by all the individual classes of alternative anticoagulant locking solutions (<a href="#CD009631-fig-0007">Figure 7</a>) (citrate locking solutions: RR 0.49, 95% CI 0.36 to 0.68; antibiotic locking solutions: RR 0.27, 95% CI 0.11 to 0.70; rt‐PA locking solutions RR 0.35, 95% CI 0.13 to 0.93) except for ethanol locks (RR 0.33, 95% CI 0.03 to 4.05). The impact on catheter‐related bacteraemia was not affected by the addition or otherwise of antimicrobial solutions to citrate locking solution (P = 0.387). </p> </section> <section id="CD009631-sec-0071"> <h4 class="title">Prevention of exit site infection</h4> <p>Exit site infection was assessed in eight studies (1199 participants, median follow‐up 4.4 months). The incidence of exit site infection was reported as the rate per patient in six studies and the rate per 1000 catheter days in two studies. No significant difference in the rate of exit site infection was found from alternative anticoagulant locking solutions (RR 0.95, 95% CI 0.58 to 1.58), nor from systemic warfarin (RR 0.79, 95% CI 0.29 to 2.16) (<a href="#CD009631-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD009631-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Exit site infection" data-id="CD009631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Exit site infection</p> </div> </div> </div> <p>Subgroup analysis did not show a reduction in the rate of exit site infection by all the individual classes of alternative anticoagulant locking solutions (citrate locking solutions: RR 0.95, 95% CI 0.60 to 1.51; antibiotic locking solutions: RR 0.91, 95% CI 0.37 to 2.25; ethanol locks: RR 2.89, 95% CI 0.12 to 67.73) (<a href="#CD009631-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD009631-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Exit site infection (subgroup analysis)" data-id="CD009631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Exit site infection (subgroup analysis)</p> </div> </div> </div> </section> <section id="CD009631-sec-0072"> <h4 class="title">All‐cause mortality</h4> <p>All‐cause mortality was reported in 11 studies (1828 participants, median follow‐up 4.4 months) assessing alternative locking solutions and systemic warfarin. No treatment class improved mortality: alternative anticoagulant locking solutions (<a href="./references#CD009631-fig-0012" title="">Analysis 1.1</a>.1 (8 studies, 1425 participants): RR 0.88, 95% CI 0.54 to 1.43; I<sup>2</sup> = 0%); warfarin <a href="./references#CD009631-fig-0012" title="">Analysis 1.1</a>.2 (3 studies, 403 participants): RR 0.78, 95% CI 0.37 to 1.65; I<sup>2</sup> = 0%). </p> <p>No individual alternative anticoagulant locking solutions showed survival benefits compared with standard heparin: citrate (<a href="./references#CD009631-fig-0013" title="">Analysis 1.2</a>.1 (6 studies, 1151 participants): RR 0.89, 95% CI 0.52 to 1.51; I<sup>2</sup> = 1%); rt‐PA (<a href="./references#CD009631-fig-0013" title="">Analysis 1.2</a>.2 (1 study, 225 participants): RR 0.63, 95% CI 0.15 to 2.56); ethanol (<a href="./references#CD009631-fig-0013" title="">Analysis 1.2</a>.3 (1 study, 49 participants): RR 2.88, 95% CI 0.12 to 67.53). </p> </section> <section id="CD009631-sec-0073"> <h4 class="title">Safety profile</h4> <p>The safety outcomes of the interventions were reported less often than efficacy outcomes. Only eight studies reported bleeding events, among which data were able to be pooled in seven studies (849 participants, median follow‐up 3.7 months) meaning these analyses maybe affected by bias associated with incomplete outcome and selective reporting. Two studies reported major bleeding only, four reported total bleeding only, and two studies reported both. </p> <p>There was no significant differences in total bleeding events for alternative anticoagulant locking solutions (<a href="./references#CD009631-fig-0014" title="">Analysis 1.3</a>.1 (3 studies, 335 participants): RR 0.69, 95% CI 0.47 to 1.01; I<sup>2</sup> = 0%), and systemic agents (<a href="./references#CD009631-fig-0014" title="">Analysis 1.3</a>.2 (3 studies, 439 participants): RR 1.30, 95% CI 0.93 to 1.83; I<sup>2</sup> = 0%). Low dose heparin reduced bleeding events by 55% although this result was based on a single study (<a href="./references#CD009631-fig-0014" title="">Analysis 1.3</a>.3 (1 study, 75 participants): RR 0.45, 95% CI 0.21 to 0.96). Subgroup analysis did not show the effect on bleeding events by any individual classes of alternative anticoagulant locking solutions: citrate locking solutions (<a href="./references#CD009631-fig-0015" title="">Analysis 1.4</a>.1 (2 studies, 286 participants): RR 0.70, 95% CI 0.47 to 1.02; I<sup>2</sup> = 0%); ethanol (<a href="./references#CD009631-fig-0015" title="">Analysis 1.4</a>.2 (1 study, 49 participants): RR 0.32, 95% CI 0.01 to 7.50); warfarin (<a href="./references#CD009631-fig-0015" title="">Analysis 1.4</a>.3 (2 studies, 259 participants): RR 1.43, 95% CI 0.86 to 2.39; I<sup>2</sup> = 0%); aspirin (<a href="./references#CD009631-fig-0015" title="">Analysis 1.4</a>.4 (1 study, 180 participants): RR 1.21, 95% CI 0.77 to 1.90); rt‐PA (<a href="./references#CD009631-fig-0015" title="">Analysis 1.4</a>.5 (1 study, 225 participants): RR 0.85, 95% CI 0.43 to 1.68). </p> <p>Five studies (633 participants) reported other adverse events, including two citrate studies (311 participants), one rt‐PA study (225 participants), one ethanol study (49 participants), and one low or no dose heparin study (48 participants). There were 53 adverse events in 335 participants in the intervention group, while 39 adverse events occurred in 298 participants in the control group. Participants receiving citrate locking solutions experienced more adverse events, including thrombocytopenia (1 study), intermittent nonspecific dizziness (1 study), metallic taste (1 study) and facial and/or digital paraesthesia (1 study). </p> </section> <section id="CD009631-sec-0074"> <h4 class="title">Requirement for thrombolytic agents</h4> <p>The requirement for rescue thrombolytic agents due to catheter malfunction was reported in eight studies, among which data were able to be meta‐analysed in seven studies (1168 participants, median follow‐up 6 months). All of the studies assessed alternative anticoagulant locking solutions. Overall, no significant effect on the requirement for thrombolytic agents was observed (<a href="#CD009631-fig-0010">Figure 10</a>: RR 0.87, 95% CI 0.55 to 1.38). With regards to individual alternative anticoagulant locking solutions, rt‐PA and LMWH reduced the use of thrombolytic agents by 79% and 47%, respectively (LMWH (1 study, 42 participants): RR 0.53, 95% CI 0.32 to 0.86; rt‐PA (1 study, 225 participants): RR 0.21, 95% CI 0.07 to 0.59), while use of citrates did not show a significant impact on the thrombolytic use (5 studies, 877 participants: RR 1.18, 95% CI 0.95 to 1.47) (<a href="#CD009631-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD009631-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Requirement for thrombolytic agents" data-id="CD009631-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Requirement for thrombolytic agents</p> </div> </div> </div> <div class="figure" id="CD009631-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Requirement for thrombolytic agents (subgroup analysis)" data-id="CD009631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Requirement for thrombolytic agents (subgroup analysis)</p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009631-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009631-sec-0075"></div> <section id="CD009631-sec-0076"> <h3 class="title" id="CD009631-sec-0076">Summary of main results</h3> <p>This systematic review of RCTs assessing the relative effects of different strategies for prevention of catheter malfunction in adults with ESKD identified 27 relatively small studies, with an average of 75 participants and 6 months follow up. Newer approaches, including alternative anticoagulant locking solutions, systemic agents and low or no dose heparin, did not affect rates of catheter malfunction compared with usual care. The only individual agent demonstrating statistically significant improvement for catheter malfunction compared with conventional care was rt‐PA‐based locking solution in a result that was based on a single study. No significant effect on all‐cause mortality was observed for individual classes of anticoagulants. Use of rt‐PA and LMWH locking solutions reduced the use of thrombolytic agents but the results were based on a single study. The relative effectiveness of other interventions remains inconclusive and, of concern, the reporting of safety outcomes was infrequent. Specifically, bleeding rates were only reported in 8 studies, despite the use of anticoagulants in a patient population with recognised bleeding risk. </p> <p>Citrate locking solutions, antibiotic locking solutions and rt‐PA locking solutions were associated with a significant reduction in catheter‐related bacteraemia. However, the additional use of antibiotic locks to citrate did not have an impact on incidence of catheter‐related bacteraemia. The effectiveness of an alternative mechanism for preventing infectious complications in haemodialysis patients with CVC, topical interventional strategies, was the subject of a Cochrane review last updated in 2010 (<a href="./references#CD009631-bbs2-0063" title="McCannM , MooreZE . Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006894.pub2] ">McCann 2010</a>). Interventions that assessed included prophylactic topical antimicrobials, topical antiseptics, medicated and non‐medicated dressings. The review found mupirocin ointment appears effective in reducing the risk of catheter‐related bacteraemia, while the effect of povidone‐iodine ointment, polysporin ointment, topical honey and types of dressing on catheter‐related bacteraemia remain uncertain. </p> <p>Among individual alternative anticoagulant agents, rt‐PA was effective in reducing catheter malfunction in a single study of Canadian centres for the prevention of catheter malfunction at no increased bleeding risk. These results are promising but, as a single study of 225 participants, require replication in other settings (<a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a>). The author’s cost‐effectiveness analysis found the incremental cost of rt‐PA was CAD 13,956 per episode of prevented catheter‐related bacteraemia in the setting where the rate of catheter‐related bacteraemia in the control group was 13%. Differences of background bacteraemia prevalence will obviously influence the cost‐effectiveness of the intervention. </p> <p>Citrate solutions reduced catheter‐related bacteraemia, but there was no clear evidence they reduced catheter malfunction. Based on a single study, citrate did not show a reduction in bleeding events. There was a suggestion that patients receiving citrate locking solutions experienced more adverse events, although these were only reported in two studies with 311 participants with one of them showing statistically significant result. Cardiac arrhythmia rates were not reported in any despite safety concerns that high concentration citrate may promote the induction of cardiac arrhythmia via systemic hypocalcaemia. Future studies should of citrate solutions are warranted and should address the uncertainty for both efficacy and safety outcomes. </p> <p>Ethanol locking solutions were not inferior to heparin locks in prevention of catheter malfunction in a single reported study. Ethanol appears to possess intrinsic anticoagulant activity and is therefore effective at restoring catheter patency (<a href="./references#CD009631-bbs2-0065" title="PenningtonCR , PithieAD . Ethanol lock in the management of catheter occlusion. Jpen: Journal of Parenteral &amp; Enteral Nutrition1987;11(5):507‐8. [MEDLINE: 3116300] ">Pennington 1987</a>). In addition, in vitro studies suggested that ethanol also has broad‐spectrum antimicrobial activity, which seems to be based on denaturization rather than a specific molecular target (<a href="./references#CD009631-bbs2-0070" title="SherertzRJ , BogerMS , CollinsCA , MasonL , RaadII . Comparative in vitro efficacies of various catheter lock solutions. Antimicrobial Agents &amp; Chemotherapy2006;50(5):1865‐8. [MEDLINE: 16641463] ">Sherertz 2006</a>). Our review did not show a benefit for ethanol on prevention of catheter‐related bacteraemia based on only one small study; future large studies should test it as a promising alternative locking solution to heparin. </p> <p>Our analysis indicates it is possible low or no dose heparin may not be inferior to heparin locking in preventing catheter malfunction based on two small studies. The uptake of heparin locking solutions for temporary dialysis access catheters appears to have developed as the default without RCT evidence. The priority that should be assigned to future research of lower dosing heparin is unclear given the scarcity of information on the rates of adverse effects associated with current heparin usage. </p> <p>The broad inclusiveness of interventions included in our review meant we anticipated heterogeneity of effects and hence planned to use random effects models. However we also found heterogeneity in the reporting methodologies. Individual studies variously reported numbers of patients experiencing events – the information conventionally used in meta‐analyses ‐ or by repeated event rates. Relative risks generated by the latter can be utilized in meta‐analysis but the narrower CI generated by repeated events mean that these studies have greater impact in the random effects models than if they had reported by individual patients. None of these studies made statistical adjustments for the potential lack of independence of repeated events in a given individual. We have developed a methodology for analysis in these situations. </p> </section> <section id="CD009631-sec-0077"> <h3 class="title" id="CD009631-sec-0077">Overall completeness and applicability of evidence</h3> <p>This is the first systematic review assessing all RCTs investigating anticoagulants for the prevention of catheter malfunction in adults undergoing haemodialysis. Twenty‐seven studies with a large variety of interventions involving six different catheter locking solutions and systemic agents were included in our review. The relative net benefit of anticoagulant therapies over conventional care for prevention of catheter malfunction remains uncertain. However, a significant reduction in catheter‐related bacteraemia was observed for citrate locking solutions, antibiotic locking solutions and rt‐PA locking solutions. Currently there is no adequate information on locking solutions collected in the Australian, USA or UK registries. The inclusion of locking solution type is warranted in large registries to facilitate the monitoring of bleeding rates and infrequent events such as cardiac arrhythmias. </p> </section> <section id="CD009631-sec-0078"> <h3 class="title" id="CD009631-sec-0078">Quality of the evidence</h3> <p>The studies were predominantly of low quality, and underpowered with an average participant number of 75 and study duration of 6 months. The interpretation of the study evidence was further limited by the variation in tested interventions and outcome reporting differences. </p> </section> <section id="CD009631-sec-0079"> <h3 class="title" id="CD009631-sec-0079">Potential biases in the review process</h3> <p>One limitation of this study was the reliance on the published data. Therefore, incomplete data reporting (attribution bias) in some studies could lead to potential loss of statistical power. In addition, assessment of potential net benefit, including efficacy and harms, was prevented by the limited safety reporting, notably of bleeding events. </p> </section> <section id="CD009631-sec-0080"> <h3 class="title" id="CD009631-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>The only agent that appeared to have prophylactic effect in our review is rt‐PA locking solution but the result was only based on a single study. This finding is consistent with those of a current systematic review (<a href="./references#CD009631-bbs2-0055" title="FirwanaBM , HasanR , FerwanaM , VaronJ , SternA , GidwaniU . Tissue plasminogen activator versus heparin for locking dialysis catheters: a systematic review. Avicenna J Med2011;1(2):29–34. [MEDLINE: 23210006] ">Firwana 2011</a>) assessing three RCTs comparing rt‐PA versus heparin for locking dialysis catheters. Only one of these was eligible for our study with the other two being excluded because they were conducted in a paediatric population (<a href="./references#CD009631-bbs2-0031" title="GittinsNS , Hunter‐BlairYL , MatthewsJN , CoulthardMG . Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. Archives of Disease in Childhood2007;92(6):499‐501. [MEDLINE: 17068072] ">Gittins 2007</a>) and another because it included patients with both acute kidney injury and chronic kidney disease <a href="./references#CD009631-bbs2-0041" title="SchenkP , RosenkranzAR , WolflG , HorlWH , TraindlO . Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. American Journal of Kidney Diseases2000;35(1):130‐6. [MEDLINE: 10620554] ">Schenk 2000</a>. </p> <p>Our review also found that use of citrate locking solutions significantly reduced incidence of catheter‐related bacteraemia but not for catheter malfunction or requirement for thrombolytic agents in 14 studies. The review is consistent in the main with a previous systematic review (<a href="./references#CD009631-bbs2-0081" title="ZhaoY , LiZ , ZhangL , YangJ , YangY , TangY , FuP . Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta‐analysis of randomized controlled trials. American Journal of Kidney Diseases2014;63(3):479‐90. [MEDLINE: 24125729] ">Zhao 2014</a>) which included 13 studies. We found citrate locking solutions had no impact on bleeding events (one eligible study), while <a href="./references#CD009631-bbs2-0081" title="ZhaoY , LiZ , ZhangL , YangJ , YangY , TangY , FuP . Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta‐analysis of randomized controlled trials. American Journal of Kidney Diseases2014;63(3):479‐90. [MEDLINE: 24125729] ">Zhao 2014</a> identified reduced bleeding with citrate locking solutions which included two studies with the results driven by inclusion of a study assessing patients with both acute kidney injury and chronic kidney disease (<a href="./references#CD009631-bbs2-0043" title="WeijmerM , van denDorpelR , vanGeelenJ , GroeneveldH , vanJaarsveldB , KoopmansM , et al. Reduction of bleeding complications in hemodialysis patients with high concentration trisodium citrate for hemodialysis catheter locking: a prospective multicenter double‐blind randomised controlled trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):737. WeijmerM , van denDorpelR , vanGeelenJ , GroeneveldH , vanJaarsveldB , KoopmansM , et al. Substantial reduction of infectious complications in hemodialysis patients with trisodium citrate 30% as catheter locking solution: a prospective multicenter double‐blind randomised controlled trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):740. [CENTRAL: CN‐00448318] WeijmerMC , Van denDorpelMA , VanGeelenJA , GroeneveldHO , VanJaarsveldBC , KoopmansMG , et al. Substantial reduction of infectious complications in hemodialysis patients with trisodium citrate 30% as catheter locking solution; a prospective multicenter double‐blind randomised controlled trial [abstract]. Journal of the American Society of Nephrology2003;14(Nov):54A. [CENTRAL: CN‐00550712] WeijmerMC , Van denDorpelMA , VanGeelenJACA , GroeneveldHO , VanJaarsveldVC , KoopmansMG , et al. Reduction of bleeding complications in hemodialysis patients with high concentration trisodium citrate for hemodialysis catheter locking; a prospective multicenter double‐blind randomised controlled trial [abstract no: F‐PO825]. Journal of the American Society of Nephrology2003;14(Nov):242A. [CENTRAL: CN‐00448317] WeijmerMC , van denDorpelMA , Van deVenPJ , ter WeePM , vanGeelenJA , GroeneveldJO , et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter‐locking solution in hemodialysis patients. Journal of the American Society of Nephrology2005;16(9):2769‐77. [MEDLINE: 16033861] ">Weijmer 2005</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009631-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Catheter malfunction" data-id="CD009631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Catheter malfunction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Catheter malfunction (subgroup analysis)" data-id="CD009631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Catheter malfunction (subgroup analysis)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Catheter‐related bacteraemia" data-id="CD009631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Catheter‐related bacteraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Catheter‐related bacteraemia (subgroup analysis)" data-id="CD009631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Catheter‐related bacteraemia (subgroup analysis)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Exit site infection" data-id="CD009631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Exit site infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Exit site infection (subgroup analysis)" data-id="CD009631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Exit site infection (subgroup analysis)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Requirement for thrombolytic agents" data-id="CD009631-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Requirement for thrombolytic agents</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Requirement for thrombolytic agents (subgroup analysis)" data-id="CD009631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Requirement for thrombolytic agents (subgroup analysis)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 1 All‐cause mortality." data-id="CD009631-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 2 Subgroup analysis of all‐cause mortality in alternative anticoagulant locking solutions." data-id="CD009631-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 2 Subgroup analysis of all‐cause mortality in alternative anticoagulant locking solutions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 3 Total bleeding events." data-id="CD009631-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 3 Total bleeding events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 4 Subgroup analysis of total bleeding events in alternative anticoagulant locking solutions." data-id="CD009631-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 4 Subgroup analysis of total bleeding events in alternative anticoagulant locking solutions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 5 Incidence of major bleeding." data-id="CD009631-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 5 Incidence of major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009631-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/urn:x-wiley:14651858:media:CD009631:CD009631-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_t/tCD009631-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Secondary outcomes, Outcome 6 Incidence of minor bleeding." data-id="CD009631-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Secondary outcomes, Outcome 6 Incidence of minor bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/media/CDSR/CD009631/image_n/nCD009631-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD009631-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Catheter malfunction events reported by study authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> <p><b>Definition of<br/> malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Overall malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Sub‐classification of catheter malfunction events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss due to<br/> malfunction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Catheter duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions<br/> to maintain<br/> catheter function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Venous occlusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Alternative anticoagulant locking solutions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0006" title="CamposRP , do NascimentoMM , ChulaDC , RiellaMC . Minocycline‐EDTA lock solution prevents catheter‐related bacteremia in hemodialysis. Journal of the American Society of Nephrology2011;22(10):1939‐45. [MEDLINE: 21852579] ">Campos 2011</a> </p> <p>BFR &lt; 200 mL/min for non‐tunnelled and 250 mL/min for tunnelled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 20/92</p> <p>Cont: 14/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 20/92</p> <p>Cont: 14/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0007" title="MacRaeJM , DojcinovicI , JungJ , ShalanskyS , LevinA , KiaiiM . 4% citrate vs heparin and the reduction of thrombosis study (CHARTS) [abstract no: SA‐PO057]. Journal of the American Society of Nephrology2006;17(Abstracts):588A. [CENTRAL: CN‐00644154] MacraeJM , DojcinovicI , DjurdjevO , JungB , ShalanskyS , LevinA , et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clinical Journal of the American Society of Nephrology: CJASN2008;3(2):369‐74. [MEDLINE: 18308996] ">CHARTS Study 2008</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 13/32</p> <p>Cont: 12/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 25%</p> <p>Cont: 17.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 55 days</p> <p>Cont: 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0010" title="DograG , HersonH , IrishAB , HutchisonB , MoodyH , Perth Renal Catheter Study Group. Prevention of tunneled haemodialysis catheter (TC) related infections using catheter restricted filling with gentamicin and citrate [abstract no: 54]. Nephrology2002;7(Suppl 3):A14. [CENTRAL: CN‐00795238] DograGK , HersonH , HutchisonB , IrishAB , HeathCH , GolledgeC , et al. Prevention of tunneled hemodialysis catheter‐related infections using catheter‐restricted filling with gentamicin and citrate: a randomized controlled study. Journal of the American Society of Nephrology2002;13(8):2133‐9. [MEDLINE: 12138146] ">Dogra 2002</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 13/42</p> <p>Cont: 16/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0011" title="FiliopoulosV , HadjiyannakosD , KoutisI , TrompoukiS , MichaT , LazarouD , et al. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial. American Journal of Nephrology2011;33(3):260‐8. [MEDLINE: 21372561] ">Filiopoulos 2011</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 9/59</p> <p>Cont: 11/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0012" title="BroomJK , KrishnasamyR , HawleyCM , PlayfordEG , JohnsonDW . A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients – the HEALTHY‐CATH trial. BMC Nephrology2012;13:146. [MEDLINE: 23121768] BroomJK , O'SheaS , GovindarajuluS , PlayfordEG , HawleyCM , IsbelNM , et al. Rationale and design of the HEALTHY‐CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology2009;10:23. [MEDLINE: 19691852] ">HEALTHY‐CATH Study 2009</a> </p> <p>Catheter removal due to flow difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0013" title="HendrickxL , KuypersD , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs2001;24(4):208‐11. [MEDLINE: 11394701] KuypersD , HendrickxL , EvenepoelP , MaesB , MessiaenT , VanrenterghemY . A comparative prospective randomized study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:232. [CENTRAL: CN‐00831907] ">Hendrickx 2001</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 5/10</p> <p>Cont: 5/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 105 non‐occlusive clots</p> <p>Cont: 44 non‐occlusive clots</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0022" title="PervezA , AhmedM , RamS , TorresC , WorkJ . Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia (cab) [abstract]. Journal of the American Society of Nephrology2000;11(Sept):194A. PervezA , AhmedM , RamS , TorresC , WorkJ , ZamanF , et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated bacteremia. Journal of Vascular Access2002;3(3):108‐13. [MEDLINE: 17639471] ">Pervez 2002</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/14</p> <p>Cont: 6/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0024" title="HemmelgarnBR , MoistL , PilkeyRM , LokC , DorvalM , TamPY , et al. Prevention of catheter lumen occlusion with rT‐PA versus heparin (Pre‐CLOT): study protocol of a randomized trial [ISRCTN35253449]. BMC Nephrology2006;7:8. [MEDLINE: 16608513] HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. New England Journal of Medicine2011;364(4):303‐12. [MEDLINE: 21268722] MannsBJ , Scott‐DouglasN , TonelliM , RavaniP , LeblancM , DorvalM , et al. An economic evaluation of rt‐PA locking solution in dialysis catheters. Journal of the American Society of Nephrology2014;25(12):2887‐95. [MEDLINE: 25012176] WardDR , MoistLM , MacraeJM , Scott‐DouglasN , ZhangJ , TonelliM , et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Canadian Journal of Kidney Health &amp; Disease2014;1:15. [MEDLINE: 25960883] ">PreCLOT Study 2006</a> </p> <p>BFR &lt; 200 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 18/110</p> <p>Cont: 36/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/110</p> <p>Cont: 1/115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0025" title="SolomonL , CheeseboroughJ , EbahL , HeapM , MillbandN , WaterhouseD , et al. A randomised, double blind, controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteraemia in patients treated with haemodialysis [abstract no:O41]. British Renal Society &amp; Renal Association Conference; 2010 May 17‐20; Manchester UK. 2010. SolomonLR , CheesbroughJS , EbahL , Al‐SayedT , HeapM , MillbandN , et al. A randomized double‐blind controlled trial of taurolidine‐citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. American Journal of Kidney Diseases2010;55(6):1060‐8. [MEDLINE: 20207458] ">Solomon 2010</a> </p> <p>Catheter loss due to occlusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/53</p> <p>Cont: 3/54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> Systematic anticoagulants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a> </p> <p>Catheter thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/20</p> <p>Cont: 9/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 75% survival at 12 months</p> <p>Cont: 36.8% survival at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 4/20</p> <p>Cont: 9/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a> </p> <p>BFR &lt; 300 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 10/81</p> <p>Cont: 33/63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a> </p> <p>BFR &lt; 300 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nor reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a> </p> <p>BFR &lt; 250 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/10</p> <p>Cont: 1/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 188 days</p> <p>Cont: 356 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a> </p> <p>BFR &lt; 150 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 8/41</p> <p>Cont: 8/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> No or low dose heparin locking solution</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0014" title="HryszkoT , BrzoskoS , MysliwiecM . Low concentration of heparin used for permanent catheters canal locking is effective and diminishes the risk of bleeding. International Urology &amp; Nephrology2013;45(3):825‐9. [MEDLINE: 22418764] ">Hryszko 2013</a> </p> <p>Catheter thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/37</p> <p>Cont: 0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 0/37</p> <p>Cont: 0/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0015" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline‐flush is sufficient to maintain patency of immobilized‐urokinase double‐lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473‐9. [MEDLINE: 15523172] ">Kaneko 2004</a> </p> <p>Catheter thrombosis or BFR &lt; 140 mL/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/26</p> <p>Cont: 1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Int: 1/26</p> <p>Cont: 1/22</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BFR ‐ blood flow rate; Cont ‐ control; Int ‐ intervention</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Catheter malfunction events reported by study authors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009631-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Warfarin dosage and target INR in systemic anticoagulant studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Background care</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0001" title="Abdul‐RahmanIS , Al‐HowaishAK . Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology2007;9(1):23‐30. [EMBASE: 2007269768] ">Abdul‐Rahman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.5 to 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinzaparin 40 to 50 IU/kg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0008" title="ColiL , DonatiG , CiancioloG , RaimondiC , ComaiG , PanicaliL , et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access2006;7(3):118‐22. [MEDLINE: 17019663] ">Coli 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.8 to 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin after catheter malfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ticlopidine 250 mg/d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0018" title="MokrzyckiMH , Jean‐JeromeK , RushH , ZdunekMP , RosenbergSO . A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney International2001;59(5):1935‐42. [MEDLINE: 11318966] MokrzyckiMH , RushH , Jean‐JeromeK , RosenbergSO . Mini‐dose warfarin for the prevention of tunneled‐cuffed catheter (TCC) thrombosis [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):213A. MokrzyckiMH , RushH , Jean‐JeromeK , ZdunekMP , RosenbergSO . Risk factors for late malfunction in tunneled‐cuffed hemodialysis catheters and the efficacy of fixed, mini‐dose warfarin [abstract]. Journal of the American Society of Nephrology2000;11(Sept):190A‐1A. [CENTRAL: CN‐00626099] ">Mokrzycki 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose warfarin 1 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin 5000 U/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0026" title="TraynorJP , WalbaumD , WooYM , TeenanP , FoxJG , MactierRA . Low‐dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrology Dialysis Transplantation2001;16(3):645. [MEDLINE: 11239055] ">Traynor 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose warfarin 1 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009631-bbs2-0027" title="WilkiesonTJ , IngramAJ , CrowtherMA , SorokaSD , NagaiR , JindalKK , et al. Low‐intensity adjusted‐dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology: CJASN2011;6(5):1018‐24. [MEDLINE: 21493739] ">Wilkieson 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable dose warfarin</p> <p>Target INR 1.5 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin 1000 to 10,000 U/mL</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>INR ‐ international normalised ratio</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Warfarin dosage and target INR in systemic anticoagulant studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/full#CD009631-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009631-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Secondary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Alternative anticoagulant locking solutions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.54, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.37, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis of all‐cause mortality in alternative anticoagulant locking solutions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.54, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Citrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.52, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.15, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Ethanol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [0.12, 67.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alternative anticoagulant locking solutions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.47, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Systemic agents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.93, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Low/no dose heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.21, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Subgroup analysis of total bleeding events in alternative anticoagulant locking solutions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Citrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Ethanol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.86, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Aspirin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.77, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 rt‐PA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.43, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Low/no dose heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.21, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Incidence of major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Incidence of minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.44, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009631.pub2/references#CD009631-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009631.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009631-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009631-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009631-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD009631-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009631-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009631\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009631\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009631\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009631\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009631.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009631.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009631.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728318628"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009631.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728318632"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009631.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec18d18d3f46e',t:'MTc0MDcyODMxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 